Lilly is developing the monoclonal antibody, bebtelovimab, which preliminary data suggests has activity against the Omicron variant and viruses with mutations to the Omicron variant. Bebtelovimab is being evaluated as a treatment of mild to moderate COVID-19 in high-risk patients.
The FDA postponed the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to discuss dosing of the Pfizer-BioNTech COVID-19 vaccine, in children 6-months to 4 years of age, until data is available on a third dose of the vaccine in young children. Data suggests that a third dose may be needed for children 2 to 5 years old. Data on a third dose is expected to be available in April.
In a final analysis of the ENSEMBLE trial, efficacy for the J&J COVID-19 vaccine against moderate to severe–critical COVID-19 was 52.9%, 28 or more days after vaccination. Efficacy was 74.6% to prevent severe–critical COVID-19
Interim results after 29-days from 458 patients enrolled in the NIH sponsored, 12-month, 950 patient, Phase I/II, MixNMatch Study (NCT04889209) examined the results of using a booster dose of the same or a different U.S. authorized COVID-19 vaccine. A booster dose increased antibody titers for all combinations of vaccines received.
A CDC analysis of vaccine effectiveness (VE) data from August 2021 to January 2022 found that VE was higher after the third dose than after the second dose but decreased over time. During the Omicron-predominant period, VE against COVID-19–associated urgent care visits and hospitalizations was 87% and 91%. during the 2 months after a third dose. VE decreased to 66% and 78% four months after a third dose. Protection was higher against hospitalizations than urgent care visits.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker